Intrepid Investor
Contributor since: 2013
Latest Articles
Roche Is Taking Amgen's BiTE Concept In Leukemia To Solid Tumors
Why Darzalex Is Growing Faster Than Revlimid, Particularly Outside The U.S.
Pfizer's Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease
Why Yervoy's Resurgence Will Gain Momentum
AbbVie Offers GARP As Consensus Forecast For Humira Is Too Pessimistic
Puma's Nerlynx: Right Drug, Wrong Target
AbbVie: Venclexta, Imbruvica Helping Patients With B Cell Malignancies
Dynavax SD-101: Right Drug In The Wrong Combo
Adaptimmune Committed To Self-Antigens While Momentum Swings Toward Cancer Neo-Antigens
BioMarin, Spark, And Insertional Oncogenesis
Celgene Has Led Bluebird Into A Crowded Field
Johnson & Johnson's Darzalex Is An Emerging Threat To The Primacy Of Celgene's Revlimid
Alnylam Teams Up With The Medicines Company To Upset PCSK9 Antibody Market
Danish Biotech Genmab Designed Johnson & Johnson's Fastest-Growing Drug
Bioverativ: Just Stop The Bleeding
Juno: How Can CAR-T's Big Loser Still Be Worth $2.5B?
Immune Synapse: Beautiful Under The Microscope, Kiss Of Death For A Cancer Cell
Ionis' Latest Attempt To Weaponize Antisense Against Cancer
Ionis Exonerated, Buying Opportunity Created By Goldman Downgrade
Why I Liquidated Most Of My Biotech Holdings
Why I Do Buy Biotech
Biogen's Little Swedish Orphan Named Sobi
Revisiting My Basket Of Biotech 'Bargains'
Expect Future Multi-Modality, Immune-Based Approaches To Solid Cancers To Include A Neoantigen Vaccine
Gilead Is Too Busy With Its Pipeline For A Big Acqusition
Like IBM, Apple Should Shrink So It Can Grow Again
AbbVie Stands For Abnormally Vulnerable
Caladrius Bio From Pawnshop To Boutique
Victory In The CAR-T Race May Be Pyrrhic, Juno The Biggest Loser, Cellectis Too Late For The Spoils
bluebird's Biotechnology Platform - An Addendum To A Recent Article
Adopt Bluebird Only If You Can Handle An Adolescent With Big Needs
Threshold Pharmaceuticals: Hard Road Toward Success